Last reviewed · How we verify
XENON XE 133
XENON XE 133 is a marketed drug used for the evaluation of pulmonary function, currently holding a significant position in its niche market. The drug's key strength lies in its unique mechanism for assessing lung function, which differentiates it from other diagnostic tools. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | XENON XE 133 |
|---|---|
| Drug class | Inhalation Diagnostic Agent [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Evaluation of Pulmonary Function
- Lung Imaging
- Assessment of Cerebral Flow
Common side effects
Key clinical trials
- Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection (PHASE3)
- A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy (PHASE3)
- Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy (PHASE1, PHASE2)
- Comparison of 133Xe Scintigraphy With 19F MRI (EARLY_PHASE1)
- Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XENON XE 133 CI brief — competitive landscape report
- XENON XE 133 updates RSS · CI watch RSS